{"drugs":["Botulism Antitoxin Heptavalent ABCDEFG Equine","Botulism Equine Heptavalent Antitoxin (ABCDEFG)"],"mono":{"0":{"id":"930459-s-0","title":"Generic Names","mono":"Botulism Equine Heptavalent Antitoxin (ABCDEFG)"},"1":{"id":"930459-s-1","title":"Dosing and Indications","sub":{"0":{"id":"930459-s-1-4","title":"Adult Dosing","mono":"<ul><li>consider administering a test dose in patients at risk of an acute hypersensitivity reaction<\/li><li>all single-use vials, regardless of size (20 mL or 50 mL) or fill volume (10 to 22 mL), contain the same minimum antitoxin potency<\/li><li><b>Botulism, Symptomatic:<\/b> test dose: 0.02 mL of a 1:1000 saline dilution INTRADERMALLY; if test is negative, repeat with a 1:100 dilution; use concurrent positive (histamine) and negative (saline) controls; positive test indicated by wheal with erythema at least 3 mm larger than negative control test; read at 15 to 20 minutes; validate with positive control test<\/li><li><b>Botulism, Symptomatic:<\/b> administer 1 single-use vial diluted 1:10 in NS via IV infusion starting at rate of 0.5 mL\/min; may double rate every 30 minutes, if tolerated; MAX infusion rate 2 mL\/min; for patients at risk of hypersensitivity reaction, begin infusion at lowest possible rate (less than 0.01 mL\/min)<\/li><\/ul>"},"1":{"id":"930459-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>consider administering a test dose in patients at risk of an acute hypersensitivity reaction<\/li><li>all single-use vials, regardless of size (20 mL or 50 mL) or fill volume (10 to 22 mL), contain the same minimum antitoxin potency<\/li><li>efficacy has not been established in pediatric patients; dosing is based on the Salisbury Rule<\/li><li><b>Botulism, Symptomatic:<\/b> test dose: 0.02 mL of a 1:1000 saline dilution INTRADERMALLY; if test is negative, repeat with a 1:100 dilution; use concurrent positive (histamine) and negative (saline) controls; positive test indicated by wheal with erythema at least 3 mm larger than negative control test; read at 15 to 20 minutes; validate with positive control test<\/li><li><b>Botulism, Symptomatic:<\/b> (infants less than 1 year of age) following dilution of single-use vial 1:10 in NS, administer 10% of diluted preparation via slow IV infusion starting at rate of 0.01 mL\/kg\/min for the first 30 minutes; may increase rate by 0.01 mL\/kg\/min every 30 minutes, if tolerated; MAX infusion rate 0.03 mL\/kg\/min; for patients at risk of hypersensitivity reaction, begin infusion at lowest possible rate (less than 0.01 mL\/min)<\/li><li><b>Botulism, Symptomatic:<\/b> (children 1 to less than 17 years of age)  following dilution of single-use vial 1:10 in NS, administer percentage of diluted preparation based on weight: 10 to 14 kg, 20%; 15 to 19 kg, 30%; 20 to 24 kg, 40%; 25 to 29 kg, 50%; 30 to 34 kg, 60%; 35 to 39 kg, 65%; 40 to 44 kg, 70%; 45 to 49 kg, 75%; 50 to 54 kg, 80%; 55 kg or greater, 100%; MAX dose: 1 vial regardless of body weight; administer via slow IV infusion starting at rate of 0.01 mL\/kg\/min for the first 30 minutes (MAX starting rate 0.5 mL\/min); may increase rate by 0.01 mL\/kg\/min every 30 minutes, if tolerated; MAX infusion rate 0.03 mL\/kg\/min (do not exceed 2 mL\/min); for patients at risk of hypersensitivity reaction, begin infusion at lowest possible rate (less than 0.01 mL\/min)<\/li><\/ul>"},"3":{"id":"930459-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Botulism, Symptomatic<br\/>"}}},"3":{"id":"930459-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930459-s-3-9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"930459-s-3-10","title":"Precautions","mono":"<ul><li>allergic reaction, delayed (serum sickness), may occur; typically within 10 to 21 days after infusion; monitoring recommended<\/li><li>blood glucose measurements may be falsely elevated; maltose in product may falsely elevate tests based on glucose dehydrogenase pyrroloquinoline-quinone (GDH-PQQ) methods; use glucose-specific meter and test strips to avoid interference<\/li><li>hypersensitivity reactions, including anaphylactic and anaphylactoid reactions, may occur; increased risk with hypersensitivity to horses or equine blood products, asthma, or hay fever; consider skin sensitivity test prior to use; monitoring recommended; discontinue use if occurs<\/li><li>infectious agent (eg, virus) transmission may occur<\/li><li>infusion reactions have occurred (eg, chills, fever, headache, nausea, vomiting, arthralgia, myalgia, fatigue, vasovagal reactions); monitoring recommended; slow the rate of infusion if such reaction occurs and discontinue infusion if symptoms worsen<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"930459-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"930459-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"930459-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Edema (1%), Hypotension (0.4%)<\/li><li><b>Dermatologic:<\/b>Pruritus (5%), Rash (2%), Urticaria (5%)<\/li><li><b>Gastrointestinal:<\/b>Nausea (1% to 5%)<\/li><li><b>Neurologic:<\/b>Headache (9%)<\/li><li><b>Other:<\/b>Fever (up to 4%), Shivering (1%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Cardiac arrest (0.4%), Hemodynamic instability (0.4%)<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction<\/li><li><b>Other:<\/b>Transfusion reaction due to serum protein reaction (less than 1%)<\/li><\/ul>"},"6":{"id":"930459-s-6","title":"Drug Name Info","sub":{"0":{"id":"930459-s-6-17","title":"US Trade Names","mono":"Botulism Antitoxin Heptavalent ABCDEFG Equine<br\/>"},"2":{"id":"930459-s-6-19","title":"Class","mono":"Antitoxin<br\/>"},"3":{"id":"930459-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"930459-s-7","title":"Mechanism Of Action","mono":"Botulism equine heptavalent antitoxin provides passive immunization against botulinum neurotoxin serotypes A, B, C, D, E, F, and G using polyclonal antibody fragments (primarily F(ab')(2) and Fab) derived from equine plasma, which bind free botulinum toxin in circulation thus preventing internalization of the toxin into target cells.<br\/>"},"8":{"id":"930459-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"930459-s-8-24","title":"Distribution","mono":"Vd: 1465 to 14172 mL <br\/>"},"3":{"id":"930459-s-8-26","title":"Excretion","mono":"Total body clearance: 137 to 1250 mL\/hr <br\/>"},"4":{"id":"930459-s-8-27","title":"Elimination Half Life","mono":"7.51 to 34.2 hours<br\/>"}}},"9":{"id":"930459-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>for IV use only<br\/><\/li><li><b>Intravenous<\/b><br\/><ul><li>if frozen, thaw product in refrigerator for approximately 14 hours; to thaw rapidly, place at room temperature for 1 hour followed by a water bath at 37 degrees C (98.6 degrees F) until thawed; do not thaw in microwave oven; do not refreeze vial<\/li><li>do not shake vial<\/li><li>dilute prior to slow IV infusion<\/li><li>monitor vital signs for tolerance; increase infusion rate incrementally as tolerated; do not exceed MAX infusion rates<\/li><li>decrease infusion rate if patient develops discomfort or infusion-related adverse events<\/li><\/ul><\/li><\/ul>"},"10":{"id":"930459-s-10","title":"Monitoring","mono":"<ul><li>reduction in severity or resolution of signs and symptoms of botulism infection may indicate efficacy<\/li><li>skin sensitivity testing; consider in patients at risk for acute hypersensitivity reactions (ie, history of hypersensitivity to horses or equine blood products, asthma, or hay fever)<\/li><li>signs and symptoms of allergic reactions, acute and delayed; particularly in patients at risk for hypersensitivity; during and up to 3 weeks after infusion<\/li><li>signs and symptoms of infusion reactions (eg, chills, fever, nausea, vomiting, headaches, arthralgia, myalgia, and fatigue or vasovagal reactions); during and immediately after infusion<\/li><li>vital signs; throughout infusion<\/li><\/ul>"},"13":{"id":"930459-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient that solution is prepared from equine plasma and may contain transmissible infectious agents.<\/li><li>Tell patient to use only glucose-specific blood glucose testing systems (ie, device and test strips) while receiving botulism equine heptavalent antitoxin due to potential for falsely elevated glucose readings from the maltose contained in product.<\/li><li>Drug may cause headache, fever, rash, hives, itching, chills, nausea, and swelling.<\/li><li>Tell patient to report signs or symptoms of an acute hypersensitivity reaction (eg, urticaria, pruritus, erythema, trouble breathing, swelling of tongue, throat, or lips, hypotension, or tachycardia) during or following the infusion.<\/li><li>Advise patient to report signs or symptoms of a delayed hypersensitivity reaction (eg, fever, rash, urticaria, arthralgia, myalgia, or swollen lymph nodes) that may occur within 1 to 3 weeks after infusion.<\/li><\/ul>"}}}